Seqirus, formerly bioCSL, manufactures and in-licenses, markets and distributes vaccines with particular focus on vaccines for the prevention and treatment of serious disease. We operate one of the world’s largest influenza vaccine manufacturing facilities and supply seasonal influenza vaccines to Australia and global markets.
In July 2015, bioCSL and the influenza vaccines of Novartis joined forces to create Seqirus, now the second largest influenza vaccine company in the world.
Working closely with public health authorities and the Australian Department of Health & Ageing we have used our influenza vaccine technology to develop and license a pandemic influenza vaccine providing biosecurity to Australia’s population in the event of an influenza pandemic such as the 2009 swine flu.We are Australia’s first line of defence against pandemic influenza.
In addition, we in-license a range of pharmaceutical products from our partner companies to ensure a comprehensive range of products are available to meet the needs of many Australians.
We manufacture a Snake Venom Detection Kit and antivenoms to protect Australia’s community from envenomation by our most venomous creatures.